We haven't covered Aimmune Therapeutics, Inc. ( AIMT ) as much as we should, barring an article comparing Aimmune and its distant competitor DBV Technologies ( DBVT ), where we said that AIMT is probably the better investment. Late last year, after DBVT withdrew its US marketing application ...

"The stock market is designed to transfer money from the active to the patient." - Warren Buffet In bioscience investment, it's crucial to filter out opinions from facts. Despite that you hold a fundamentally sound company, you will face streams of negative market opinions. To stay grounde...

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it has randomized its first patient in a phase 2 clinical trial of AR201 for the treatment of egg allergy. AR201, an investigational biologica...